期刊文献+

国产缬沙坦与进口培垛普利治疗原发性高血压的药物经济学分析 被引量:2

Domestic Valsartan vs. Imported Perindopril in the Treatment of Essential Hypertension:Pharmacoeconomic Analysis
下载PDF
导出
摘要 目的:比较国产缬沙坦(缬克)与进口培哚普利(雅施达)治疗轻中度原发性高血压的临床疗效和费用。方法:70例轻、中度原发性高血压患者随机口服国产缬沙坦80 mg.d-1或进口培哚普利4 mg.d-1,4周末诊室坐位舒张压≥90 mmHg者剂量分别加倍至160 mg.d-1和8 mg.d-1,继续服用4周。结果:治疗前两组间各参数基线水平差异无统计学意义(P>0.05),8周末缬沙坦组和培哚普利组总有效率分别为79.4%和80.6%(P>0.05),缬沙坦组收缩压和舒张压分别下降23.4 mmHg和11.7 mmHg,培哚普利组收缩压和舒张压分别下降22.8 mmHg和12.1 mmHg,(P>0.05)。缬沙坦组和培哚普利组每月人均治疗费用分别为105元和124元。结论:国产缬沙坦与进口培哚普利治疗原发性高血压疗效没有差别,但国产缬沙坦成本更低,服药依从性及耐受性更好。 OBJECTIVE: To evaluate the clinical efficacy and cost of domestic valsartan vs.imported perindopril(Acertil) for mild-to-moderate essential hypertension.METHODS: 70 patients with mild-to-moderate essential hypertension were randomized to receive either domestic valsartan(80 mg daily) or imported perindopril(4 mg daily) for a total of 8 weeks,however,doses were doubled to 160 mg daily vs.8 mg daily at the end of 4 weeks for patients with seated diastolic blood pressure ≥90 mmHg.RESULTS: No statistical significance was noted in the differences of baseline data between the two groups(P 〉 0.05).At the end of 8 weeks,the total effective rate in patients receiving domestic valsartan was 79.4%,as compared with 80.6% in patients receiving imported perindopril(P 〉 0.05);systolic blood pressure(SBP) and diastolic blood pressure(DBP) decreased by 23.4 mmHg and 11.7 mmHg,respectively in domestic valsartan group,as compared with a reduction of 22.8 mmHg and 12.1 mmHg in the imported perindopril group(P 〉 0.05).The monthly average treatment cost per patient was 105 Yuan for patients receiving domestic valsartan,as compared with 124 Yuan for patients receiving imported perindopril.CONCLUSION: There were no differences in curative efficacy between the domestic valsartan and the imported perindopril in the treatment of essential hypertension,but domestic valsartan has lower cost and to which patients have better medication compliance and tolerability.
出处 《中国医院用药评价与分析》 2011年第2期161-163,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 缬沙坦 培哚普利 原发性高血压 成本-效果分析 Valsartan Perindopril Essential hypertension Cost-effectiveness analysis
  • 相关文献

参考文献5

  • 1林曙光,陈鲁原.治疗高血压的药物经济学评价[J].中华心血管病杂志,2003,31(3):236-237. 被引量:40
  • 2Reboldi G, Angeli F, Cavallini C, et al. Comparision between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke, death : a meta-analysis [ J ]. J Hypertens, 2008,26(7) :1282. 被引量:1
  • 3Elliott W J, Plauschinat CA, SkrePnek GH, et al. Persistence, adherence, and risk of discontinuation. associated with commonly prescribed antihypertensive drug monotherapies [ J]. J Am Board Faro Med,2007,20 (1) :72. 被引量:1
  • 4Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy[J].Am J Hypertens, 2006,19 ( 11 ) , 1190. 被引量:1
  • 5安富荣,沈金芳.国产与进口缬沙坦胶囊的质量评价[J].中国药房,2007,18(4):291-292. 被引量:5

二级参考文献10

  • 1Degli EE, Berto P, Ruffo P, et al. The PANDORA project: result of the cost of illness analysi. J Hum Hypertents. 2001. 15:329-334. 被引量:1
  • 2Degli EE, Sturani A, Degli EL, et al. Pharmacoutilization of antihypertensive drugs: a model of analysis. Int J Clin Pharmacol Ther ,2001,39:251-258. 被引量:1
  • 3Johannesson M, Dahlof B, Lintholm LH, et al. The cost-effectiveness of treating hypertension in elderly people-an analysis of the Swedish TrialOld Patients with Hypertension (STOP Hypertension). J Intern Med ,1993,234 : 317-323. 被引量:1
  • 4Cost effectiveness of combination therapy. Based on a presentation by Daniel Hilleman, Pharm D. Am J Manag Care , 1999, 5( Suppl 7):S449-454. 被引量:1
  • 5Dunn EC, Small RE. Economic of antihypertensive therapy in the elderly. Drugs Anging ,2001, 18: 515-525. 被引量:1
  • 6Pearce KA, Furberg CD, Psaty BM, et al. Cost-mininization and the number need to treat in uncomplicated hypertension. Am J Hypertens,1998, 11:618-629. 被引量:1
  • 7Ramsey SD, Neil N, Sullivan SD, et al. An economic evaluation of the JNC hypertension guidelines using data from randomized controlled trial. Am Board Fam Prac, 1999, 12: 105-114. 被引量:1
  • 8Elliott WJ, Weir DR, Black HR. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Arch Intern Med, 2000, 160: 1277-1283. 被引量:1
  • 9徐端正.药物经济学及其分析[J].中国新药与临床杂志,2000,19(2):139-142. 被引量:487
  • 10杜娟,徐学明.缬沙坦对慢性肾衰竭合并高血压患者血浆内皮素的影响及临床意义[J].中国药房,2002,13(11):675-676. 被引量:7

共引文献43

同被引文献24

引证文献2

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部